Akt inhibitors: mechanism of action and implications for anticancer therapeutics

被引:30
|
作者
Bhutani, Jaikrit [1 ]
Sheikh, Asfandyar [2 ,4 ]
Niazi, Asfandyar Khan [3 ]
机构
[1] Post Grad Inst Med Sci, Rohtak, Haryana, India
[2] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[3] Shifa Coll Med, Islamabad, Pakistan
[4] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan
来源
关键词
SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-SURVIVAL; KINASE; GROWTH; CARCINOMAS; EXPRESSION; ONCOGENE; PATHWAY; GLIOBLASTOMAS;
D O I
10.1186/1750-9378-8-49
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Angiotensin-converting enzyme inhibitors: Mechanism of action and implications in anesthesia practice
    Behnia, R
    Molteni, A
    Igic, R
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (09) : 763 - 776
  • [32] Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
    Chen, Hao
    Smaill, Jeff B.
    Liu, Tongzheng
    Ding, Ke
    Lu, Xiaoyun
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (23) : 14404 - 14424
  • [33] Discovery of c-Met kinase inhibitors for anticancer therapeutics.
    Yun, Chang-Soo
    Cho, Sung Yun
    Kim, Hyoung Rae
    Jung, Hee Jung
    Ha, Jae D.
    Lee, Kwangho
    Kim, Pilho
    Park, Chi Hoon
    Lee, Chong Ock
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [34] Allosteric Hsp70-family inhibitors as targeted anticancer therapeutics
    Koren, John
    Xu, Chao
    Rodina, Anna
    Shrestha, Liza
    Taldone, Tony
    Chiosis, Gabriela
    CANCER RESEARCH, 2015, 75
  • [35] Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
    Zhang, Cunlong
    Tan, Chunyan
    Ding, Huaiwei
    Xin, Tian
    Jiang, Yuyang
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (20) : 2921 - 2935
  • [36] Screening and identification of new generation glucose transporter inhibitors as anticancer therapeutics
    Qian, Yanrong
    Shriwas, Pratik
    Wang, Xuan
    Roberts, Dennis
    Kessler, Emma
    Bergmeier, Stephen
    Chen, Xiaozhuo
    CANCER RESEARCH, 2017, 77
  • [37] MECHANISM OF ACTION OF CYCLOOXYGENASE INHIBITORS
    LANDS, WEM
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1986, 11 (02) : 203 - 203
  • [38] Mechanism of action of the calcineurin inhibitors
    Halloran, PF
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3067 - 3069
  • [39] AN ANTICANCER DRUG-SENSITIVE MURINE ERYTHROLEUKEMIA CLONE - IMPLICATIONS FOR THE MECHANISM OF ACTION OF ANTINEOPLASTIC DRUGS
    DINNEN, RD
    ROBINOW, CF
    EBISUZAKI, K
    CANCER RESEARCH, 1993, 53 (08) : 1877 - 1882
  • [40] Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride
    Guo, ML
    Guo, ZJ
    Sadler, PJ
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2001, 6 (07): : 698 - 707